Clinical Trials / Research Studies
Leukemia AML New Diagnosis

Leukemia Research Studies

< Back to Pediatric Cancer Research Studies Page

AML New Diagnosis

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

  • Ages: From 3 to 36 months old

PURPOSE: This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killin ...More

AAML1831: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Ages: up to 22 Years (Child, Adult) 

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.